Shield Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	10.81	6.52	13.95	3.4	16.41	4.01
Cash & Short-Term Investments	10.81	6.52	13.95	3.4	16.41	4.01
Cash Growth	33.52%	-53.23%	309.99%	-79.27%	308.75%	-26.81%
Accounts Receivable	23.69	12.28	9.99	3.39	1.1	0.3
Other Receivables	0.11	10.54	1.23	1.13	1.3	0.6
Receivables	23.8	22.81	11.21	4.52	2.4	0.9
Inventory	6.75	5.66	3.2	1.76	2.21	1.88
Prepaid Expenses	-	2.44	2.9	2.5	2.35	0.35
Restricted Cash	-	0.5	-	-	-	-
Total Current Assets	41.36	37.94	31.26	12.17	23.37	7.14
Property, Plant & Equipment	0.23	0.37	0.67	0.24	0.41	0.04
Other Intangible Assets	1.08	1.05	1.18	1.23	23.46	25.71
Long-Term Deferred Charges	18.43	17.12	15.68	12.98	12.9	11.51
Other Long-Term Assets	1	1	-	-	-	-
Total Assets	62.1	57.48	48.8	26.62	60.14	44.41
Accounts Payable	36.92	6.52	4.05	1.74	1.78	0.54
Accrued Expenses	-	16.67	8.67	9.71	2.9	1.47
Current Portion of Leases	0.1	0.2	0.21	0.11	0.21	0.04
Current Income Taxes Payable	-	0.05	0.1	0.27	0.07	0.92
Other Current Liabilities	12.99	9.19	0.7	1.01	0.08	0.11
Total Current Liabilities	50.01	32.62	13.74	12.83	5.04	3.07
Long-Term Debt	26.95	26.17	19.84	6.68	-	-
Long-Term Leases	-	-	0.2	-	-	-
Other Long-Term Liabilities	-	-	-	0.56	-	-
Total Liabilities	76.96	58.8	33.77	20.07	5.04	3.07
Common Stock	19.91	19.91	15.01	5.37	4.38	2.41
Additional Paid-In Capital	203.19	203.19	198.76	169.48	155.15	120.63
Retained Earnings	-269.02	-259.85	-233.53	-201.11	-144.8	-120.49
Comprehensive Income & Other	31.06	35.43	34.79	32.8	40.36	38.79
Total Common Equity	-14.86	-1.32	15.03	6.54	55.1	41.34
Shareholders' Equity	-14.86	-1.32	15.03	6.54	55.1	41.34
Total Liabilities & Equity	62.1	57.48	48.8	26.62	60.14	44.41
Total Debt	27.05	26.37	20.25	6.79	0.21	0.04
Net Cash (Debt)	-16.23	-19.85	-6.3	-3.39	16.2	3.98
Net Cash Growth	-	-	-	-	307.37%	-27.16%
Net Cash Per Share	-0.02	-0.03	-0.01	-0.01	0.08	0.03
Filing Date Shares Outstanding	1,042	1,042	782.06	259.39	215.89	117.62
Total Common Shares Outstanding	1,042	1,042	782.06	259.39	215.89	117.62
Working Capital	-8.64	5.32	17.53	-0.66	18.33	4.07
Book Value Per Share	-0.01	-0.00	0.02	0.03	0.26	0.35
Tangible Book Value	-15.93	-2.36	13.85	5.31	31.64	15.62
Tangible Book Value Per Share	-0.02	-0.00	0.02	0.02	0.15	0.13
Machinery	-	0.51	0.48	0.24	0.27	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.